Seroatlas · Human Serome Atlas

URAD

Putative 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase

Also known as: PRHOXNB, URAD_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: A6NGE7
Gene: URAD
Ensembl: ENSG00000183463
Chromosome: 13
Canonical length: 173 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase activity. Predicted to be involved in amide catabolic process; nucleobase-containing small molecule metabolic process; and urate catabolic process. Predicted to be active in peroxisome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

173 residues, UniProt reviewed canonical sequence.

>A6NGE7|URAD
     1  MDIEKVNSMD LGEFVDVFGN ATERCPLIAA AVWSQRPFSD LEDLEKHFFA FIDALAQSGQ
    61  EGILRCHPDL AGSELQRGTL TAESQREQSG AGLRSLGADE RLRLAELNAQ YRARFGFPFV
   121  LAARFSDRTA VPRELARRLL CPSAQELRTA LGEVKKIGSL RLADLLRADP AKL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against URAD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.27
Highest tissue expression: 23 nTPM

Expression across tissuesHPA

Tissue

colon: 23 nTPM
small intestine: 16 nTPM
duodenum: 7.4 nTPM
appendix: 1.6 nTPM
rectum: 0.9 nTPM
cerebellum: 0.7 nTPM

Single-cell type

enterocytes: 166 nCPM
goblet cells: 102 nCPM
enteric transient amplifying cells: 70 nCPM
colonocytes: 59 nCPM
enteric stem cells: 56 nCPM
paneth cells: 46 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebellum: 1.5 nTPM
cerebral cortex: 0.3 nTPM
medulla oblongata: 0.3 nTPM
pons: 0.3 nTPM
midbrain: 0.2 nTPM
spinal cord: 0.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.89
gnomAD pLI: 0.01
gnomAD missense Z: -0.36
DepMap mean gene effect: 0.03
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

carboxy-lyase activity

Cellular components

peroxisome

Protein domainsUniProt · Pfam · InterPro

2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase, type 1
Oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase
Oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase superfamily
OHCU decarboxylase

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads URAD as an antibody target. Whether an autoantibody or antibody against URAD could matter depends on whether native URAD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

URAD is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label URAD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...